Presenilin, Notch, and the genesis and treatment of Alzheimer's disease
AUTOR(ES)
Selkoe, Dennis J.
FONTE
The National Academy of Sciences
RESUMO
Elucidation of the proteolytic processing of the amyloid β-protein precursor (APP) has revealed that one of the two proteases (γ-secretase) that cleave APP to release amyloid β-protein (Aβ) is likely to be presenilin. Presenilin also mediates the γ-secretase-like cleavage of Notch receptors to enable signaling by their cytoplasmic domains. Therefore, APP and Notch may be the first identified substrates of a unique intramembranous aspartyl protease that has presenilin as its active-site component. In view of the evidence for a central role of cerebral build-up of Aβ in the pathogenesis of Alzheimer's disease, this disorder appears to have arisen in the human population as a late-life consequence of the conservation of a critical developmental pathway.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=58679Documentos Relacionados
- Treatment of Alzheimer's disease.
- De novo presenilin 1 mutations are rare in clinically sporadic, early onset Alzheimer's disease cases. French Alzheimer's Disease Study Group.
- Alzheimer's disease: a treatment in sight?
- Forebrain degeneration and ventricle enlargement caused by double knockout of Alzheimer's presenilin-1 and presenilin-2
- Medication reconciliation role and value in Alzheimer's disease treatment
